Wall Street is positive on Immunic Inc (IMUX). On average, analysts give IMUX a Strong Buy rating. The average price target is $55.625, which means analysts expect the stock to gain by 171.34% over the next twelve months.
That average ranking earns IMUX an Analyst Rating of 78, which is better than 78% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported.
InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.
What's Happening With Immunic Inc Stock Today?
Immunic Inc (IMUX) stock is up 4.57% while the S&P 500 has fallen -0.01% as of 2:13 PM on Tuesday, Feb 9. IMUX has gained $0.90 from the previous closing price of $19.61 on volume of 228,682 shares. Over the past year the S&P 500 has risen 16.80% while IMUX has gained 129.82%. IMUX lost -$3.14 per share the over the last 12 months.
Click Here to get the full report on Immunic Inc (IMUX) Stock.
